



AFFIDAVIT OF NATHANIEL E FRANK-WHITE

1. I am a Records Request Processor at the Internet Archive. I make this declaration of my own personal knowledge.
2. The Internet Archive is a website that provides access to a digital library of Internet sites and other cultural artifacts in digital form. Like a paper library, we provide free access to researchers, historians, scholars, and the general public. The Internet Archive has partnered with and receives support from various institutions, including the Library of Congress.
3. The Internet Archive has created a service known as the Wayback Machine. The Wayback Machine makes it possible to browse more than 450 billion pages stored in the Internet Archive's web archive. Visitors to the Wayback Machine can search archives by URL (i.e., a website address). If archived records for a URL are available, the visitor will be presented with a display of available dates. The visitor may select one of those dates, and begin browsing an archived version of the Web. Links on archived files in the Wayback Machine point to other archived files (whether HTML pages or other file types), if any are found for the URL indicated by a given link. For instance, the Wayback Machine is designed such that when a visitor clicks on a hyperlink on an archived page that points to another URL, the visitor will be served the archived file found for the hyperlink's URL with the closest available date to the initial file containing the hyperlink.
4. The archived data made viewable and browsable by the Wayback Machine is obtained by use of web archiving software that automatically stores copies of files available via the Internet, each file preserved as it existed at a particular point in time.
5. The Internet Archive assigns a URL on its site to the archived files in the format `http://web.archive.org/web/[Year in yyyy][Month in mm][Day in dd][Time code in hh:mm:ss]/[Archived URL]` aka an "extended URL". Thus, the extended URL `http://web.archive.org/web/19970126045828/http://www.archive.org/` would be the URL for the record of the Internet Archive home page HTML file (`http://www.archive.org/`) archived on January 26, 1997 at 4:58 a.m. and 28 seconds (1997/01/26 at 04:58:28). The date indicated by an extended URL applies to a preserved instance of a file for a given URL, but not necessarily to any other files linked therein. Thus, in the case of a page constituted by a primary HTML file and other separate files (e.g., files with images, audio, multimedia, design elements, or other embedded content) linked within that primary HTML file, the primary HTML file and the other files will each have their own respective extended URLs and may not have been archived on the same dates.
6. Attached hereto as Exhibit B are true and accurate copies of printouts of the Internet Archive's records of the archived files for the URLs and the dates specified in the attached coversheet of each printout.



7. I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

DATE: 03/26/2024

Nathaniel Frank-White

Nathaniel E Frank-White

Please see attached
All Purpose
Jurat form
for additional
Notary Events

EXHIBIT B

https://web.archive.org/web/20060316092055/http://www.regeneron.com/investor/Regn_LM_Mar06.pdf

Regeneron Pharmaceuticals, Inc.

**Lehman Brothers
9th Annual Global Healthcare Conference
March 8, 2006**



Safe Harbor Statement

Except for historical information, the matters contained in this presentation may constitute forward-looking statements that involve risks and uncertainties, including uncertainties related to product development and clinical trials, unforeseen safety issues resulting from the administration of products in patients, uncertainties related to the need for regulatory and other government approvals, patents and proprietary technology, the need for additional capital, uncertainty of market acceptance of Regeneron's product candidates, the receipt of future payments, the continuation of business partnerships, and additional risks detailed from time to time in Regeneron's filings with the Securities and Exchange Commission (SEC). Please refer to Regeneron's recent Forms 10-K, 10-Q, and 8-K for additional information on the uncertainties and risk factors related to our business. Because forward-looking statements involve risks and uncertainties, actual results may differ materially from current results expected by Regeneron. Regeneron is providing this information as of the original date of this presentation and expressly disclaims any duty to update any information contained in these materials.

REGENERON



Regeneron Overview

- **3 major clinical programs**
 - Oncology
 - Eye Diseases
 - Inflammatory Diseases
- **Major collaboration with sanofi-aventis**
- **Manufacturing expertise at 10,000 liter scale**
- **Next generation platform for monoclonal antibodies**
- **Strong financial position**
 - **Approximately \$316 million cash on hand at 12/31/05**

REGENERON



Current Events

■ Oncology

- Three phase 2 trials announced
- Completing preparations for combination studies
- FDA submission targeted for 2007/2008 timeframe

■ Eye diseases

- Reported positive preliminary results in wet AMD
- Phase 2 study ready to go
- Phase 3 planned for initiation early 2007

■ IL-1 Trap – Inflammatory Diseases

- Phase 3 study enrollment on plan
- BLA submission targeted for 1H 2007

■ Human monoclonal antibody platform

- Source of new drug candidates and potential partnerships

REGENERON



“Mechanism” vs. “Execution” Risk

■ Mechanism Risk

- Target not validated; no approved products with same molecular target
- Mechanism-based toxicity ill-defined
- Historically high rate of failure

■ Execution Risk

- Approved product validates molecular target and safety profile
- Higher probability of successful development
- 2nd and 3rd entries to “blockbuster” categories have history of strong commercial success

REGENERON



Regeneron Clinical Product Candidates

- Each candidate designed to address clinically validated target
- Each has opportunity to expand to new disease settings
- Clinical evidence already obtained indicating that each candidate addresses its target
- Regulatory approval strategy defined for each candidate

Execution vs. Mechanism Risk!

REGENERON



VEGF Trap Oncology

The sanofi-aventis Collaboration

Strong partner

- Leader in oncology marketplace
- Expertise in clinical development and therapeutic research
- Sanofi-aventis leads the global development program

Commitment to broad VEGF Trap oncology program

- Single agent studies
- Chemotherapy combination studies
- Expanding number of therapeutic indications

Favorable financial opportunity for Regeneron

- sanofi-aventis funds global development
 - Repayment of 50% out of profits according to formula
- \$400 MM in commercial approval milestones
- 50:50 global profit split (35% royalty in Japan)
- Co-promotion rights

REGENERON




Blocking VEGF with VEGF Trap

- **Clinical evidence that VEGF Trap can address “VEGF target”**
 - Blood samples demonstrate “trapping” of VEGF
 - Decreased perfusion/vascular permeability after single dose
 - Adverse events of hypertension and proteinuria; expected based on Avastin® results
 - Responses observed in individual patients previously treated with multiple chemotherapy regimens

REGENERON




Targeting the VEGF Pathway



Comparison of VEGF Trap and Avastin®

VEGF Trap has markedly higher affinity for VEGF than Avastin based on in vitro bioassay



IC50 for VEGF Trap = 44pM

IC50 for Avastin = 1400pM

REGENERON



VEGF Trap Oncology

Single Agent Studies in Late-stage Cancer Patients

- **Non-small Cell Lung Adenocarcinoma (NSCLA)**
 - Trial initiated January 2006
 - Single arm, open label design
 - Primary endpoint objective response rate
- **Ovarian Cancer**
 - Randomized comparison of 2 doses of VEGF Trap
- **Symptomatic Malignant Ascites (SMA)**
 - Randomized, placebo controlled study
 - Fast track designation granted by FDA

REGENERON




Preliminary Anti-tumor Activity Ovarian Cancer Patient

VEGF Trap 4.0 mg/kg IV biweekly x 4

Baseline

Week 8



Diagnosis: Recurrent Advanced Ovarian Epithelial Adenocarcinoma

Prior Treatments: Carboplatinum + Paclitaxel; Carboplatinum + Gemcitabine

REGENERON




Symptomatic Malignant Ascites

Complete Resolution after 4 Doses of VEGF Trap

VEGF Trap 4.0 mg/kg IV biweekly x 4

Baseline

Week 8



Prior Treatments: Carboplatinum + Paclitaxel; Carboplatinum + Gemcitabine

REGENERON



VEGF Trap Oncology

VEGF Trap Studies in Combination with Standard Chemotherapy Regimens

- 5 phase 1b studies in different chemotherapy regimens
 - 3 trials initiated in 2005
 - 2 additional trials to begin in near term
- Efficacy studies to begin 2H 2006
 - 2 studies currently in late-stage planning

REGENERON



VEGF Trap Oncology

VEGF Trap Studies being planned with National Cancer Institute

- National Cancer Institute to conduct trials of VEGF Trap under Clinical Trials Agreement between CTEP, NCI, and sanofi-aventis
- Up to 10 efficacy/safety studies planned for 2006

REGENERON



VEGF Trap Oncology Summary

- VEGF confirmed as validated target
- Preliminary clinical evidence already obtained that VEGF Trap addresses target
- Clinical program being rapidly expanded
- Sanofi-aventis responsible for execution of clinical trials
- Submission for approval planned for 2007/2008 timeframe

REGENERON



VEGF Trap – Eye Development Program

- Wet AMD is major cause of blindness in adults over 60
- Blocking VEGF validated as a means to treat wet AMD
- Opportunity for VEGF Trap – Eye to emerge as “best-in-class” treatment for wet AMD
 - Potential for greater efficacy related to unique characteristics
 - Higher affinity for VEGF than Lucentis®
 - Ability to block all forms of VEGF-A and Placental Growth Factor (PIGF)
 - Potential for greater patient convenience/safety by requiring less frequent injections
- Positive preliminary phase 1 data reported

REGENERON



Phase 1 Intravitreal Trial

- Dose-ascending cohorts of 3-6 subjects given single intravitreal injection to determine maximum tolerated dose
- Primary endpoint safety and tolerability
 - Ocular coherence tomography (OCT) to assess retinal thickness
- Status and preliminary results
 - Dose levels of 0.05, 0.15, 0.5, 1.0, 2.0, and 4.0 mg completed
 - All planned dose levels completed: maximum tolerated dose not reached
 - Rapid, substantial, and prolonged (up to at least 4 weeks) reduction in retinal thickness demonstrated by OCT

REGENERON



Intravitreal VEGF Trap – Eye

1.0 mg Single Dose

Baseline: 732 μ



Week 1: 196 μ



Week 2: 168 μ



Week 8: 182 μ



REGENERON



VEGF Trap – Eye Summary

- **Confirmed evidence of biological activity**
 - Rapid and substantial reduction in retinal thickness
 - Prolonged effect appears to be at least 4 weeks
- **Positioned for rapid expansion of program**
 - Phase 2 wet AMD trial to begin in next few months
 - New indications being reviewed
- **Phase 3 program in US likely to be comparison to ranibizumab (Lucentis™)**
 - Initiation of phase 3 planned for 1Q 07
- **Additional data at ARVO 2006**

REGENERON



The IL-1 Trap Development Program

**Registration study initiated in rare genetic diseases
4Q 2005**



**Proof-of-concept trial initiated in
Systemic Onset Juvenile Idiopathic Arthritis (SJIA)
4Q 2005**

REGENERON



IL-1 Trap CAPS POC Study (5 patients)

- IL-1 Trap rapidly and dramatically:
 - Improves subjective measures of disease
 - Lowers blood markers of inflammation (e.g., CRP, SAA, ESR)
 - “Traps” IL-1 and convincingly confirms markedly increased IL-1 levels in this disease
- No significant safety concerns noted in small pilot study



* : $p < 0.05$ for comparison to baseline

* : $p < 0.05$ for comparison to baseline

The daily diary score is the sum of symptoms on an ordinal (0-4) scale. Symptoms include fever, rash, joint pain, headache, hearing loss, fatigue, sleep problems, eye redness, & difficulties walking

REGENERON



IL-1 Trap CAPS Registration Study

- Orphan drug designation
- 160 mg/week dose
- Study phases include
 - 6 month placebo controlled, double blind (efficacy/safety)
 - 6 month label extension (safety)
- Study cohort identified and enrollment in progress
 - Enrollment on target for completion 1H 06
 - BLA submission planned for 1H 2007

REGENERON



Velocimmune: Proprietary New Approach for Therapeutic Human Monoclonal Antibodies

- Produces wide variety of high affinity human antibodies against target
- Synergizes with commercial-scale manufacturing and proprietary approach to cell line development
- Applicable to both validated and novel targets
- Overcomes many issues currently used to produce human antibodies

Future Pipeline Development Platform

REGENERON



Regeneron's major development programs mid 2007: future plans

■ Oncology

- 3 single agent efficacy studies well under way
- 3 large studies in combination with chemotherapy underway
- About 12 studies underway in collaboration with NCI CTEP program

■ Eye

- Phase 2 data completed and data reported
- Phase 3 underway in AMD
- Additional indications being explored

■ IL-1 Trap

- BLA submitted for CAPS
- Phase 3 under way for systemic onset JIA

REGENERON



Regeneron Pharmaceuticals, Inc.

**Lehman Brothers
9th Annual Global Healthcare Conference
March 8, 2006**



JURAT ATTACHMENT


A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

STATE OF Texas }

COUNTY OF Tarrant }

The foregoing instrument was subscribed and sworn before me this date of
03/26/2024, by Nathaniel Frank-White

This notarial act was an online notarization.



Notary's Signature Brittany Rene Copeland

Registration No.: 133645929

Document Notarized using a Live Audio-Video Connection

Commission Expiration Date: March 15, 2026